Fredag 7 November | 10:48:18 Europe / Stockholm

Kalender

Est. tid*
2026-02-05 08:30 Bokslutskommuniké 2025
2025-11-13 08:30 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2025-05-28 - Årsstämma
2025-05-15 - Kvartalsrapport 2025-Q1
2025-02-06 - Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-10-30 - Split EXPRS2 40:1
2024-08-15 - Kvartalsrapport 2024-Q2
2024-06-07 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2024-06-05 - Årsstämma
2024-05-16 - Kvartalsrapport 2024-Q1
2024-02-08 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2023-05-24 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-03-23 - Extra Bolagsstämma 2023
2023-02-09 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2022-05-25 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2021-05-26 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-23 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2020-05-26 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2019-05-23 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-22 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2018-05-24 - Årsstämma
2018-05-17 - Kvartalsrapport 2018-Q1
2018-02-07 - Bokslutskommuniké 2017
2017-11-30 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-06-01 - X-dag ordinarie utdelning EXPRS2 0.00 SEK
2017-05-31 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-04-19 - Extra Bolagsstämma 2017
2017-02-28 - Bokslutskommuniké 2016
2016-11-08 - Kvartalsrapport 2016-Q3
2016-08-31 - Kvartalsrapport 2016-Q2

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
ExpreS2ion är ett bioteknikbolag fokuserat på utveckling av vacciner. Bolagets mål att bidra till hälso- och sjukvården genom att utveckla vacciner ämnade att stödja sjukdomsförebyggande och förbättra livskvaliteten globalt. ExpreS2ion använder sin ExpreS2™-teknologiplattform, som har validerats i kliniska fas III-studier, för utveckling och produktion av vaccinkomponenter. Bland pågående projekt utvecklar bolaget ES2B-C001, ett HER2-cVLP bröstcancervaccin som genomgår kliniska fas I-prövningar.
2024-12-06 15:00:00
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 6 December 2024 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces the outcome of the exercise of warrants of series TO 10, which were issued in connection with the Company's rights issue of units in 2024. In total, 22,322,680 warrants of series TO 10 were exercised, corresponding to approximately 69 percent of the total number of outstanding warrants of series TO 10, for subscription of 558,067 shares at an exercise price of SEK 17.91 per share. ExpreS2ion will receive approximately SEK 10 million before issuing costs through the exercise of the warrants of series TO 10.

Background
ExpreS2ion completed a rights issue of units during the third quarter of 2024. Within the scope of the rights issue, ExpreS2ion issued 30,046,672 warrants of series TO 10. Furthermore, ExpreS2ion issued an additional 2,175,000 warrants of series TO 10 to guarantors in the rights issue who chose to receive guarantee compensation in units.

Prior to recalculation of the warrants of series TO 10, one (1) warrant of series TO 10 gave the owner the right to subscribe for one (1) new share in the Company. Following the recalculation of the warrants, forty (40) warrants of series TO 10 gave the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO 10 was defined as 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from 1 November 2024 to 14 November 2024, but not less than the share's quota value (SEK 4.444444) (previously SEK 0.111111) and not more than SEK 60 (previously SEK 1.5) per share after recalculation. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 25.59, therefore the exercise price for the warrants of series TO 10 was set to SEK 17.91.

Outcome
In total, 22,322,680 warrants of series TO 10 were exercised for subscription of 558,067 shares, meaning that approximately 69 percent of all outstanding warrants of series TO 10 were exercised for subscription of shares and that ExpreS2ion receives approximately SEK 10 million in gross proceeds.

Exercised warrants of series TO 10 have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three weeks.

Number of shares, share capital and dilution
Through the exercise of the warrants of series TO 10, the number of shares in ExpreS2ion increases by 558,067 shares to a total of 2,658,346 shares. The share capital will increase by SEK 2,480,297.782278 to SEK 11,814,871.132548.

For existing shareholders who did not exercise any warrants of series TO 10, the dilution amounts to approximately 21 percent based on the number of shares following exercise of the warrants of series TO 10.

CEO Bent U. Frandsen's comments:
“We are grateful for the continued support from our investors during this warrant subscription process. The funds raised will provide important resources to further advance our strategic priorities, including the recently approved Phase I clinical trial for our HER2-expressing cancer vaccine. This approval marks a major milestone for ExpreS2ion and reflects our commitment to driving innovation in the fight against cancer. While we remain focused on executing our plans and delivering value to our shareholders, we also recognize the challenges in today’s market environment and are committed to managing our resources effectively to achieve meaningful progress.”

Advisors
Vator Securities acts as financial advisor and issuing agent to the Company in connection with the transaction. Advokatfirman Schjødt is the Company's legal advisor in connection with the transaction.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB